7.5 DEVELOPMENT FUNDS Developmental Funds comprise one of the most important tools the Arizona Cancer Center director has to enhance the Center and to meet future goals and initiatives. Throughout its history, the AZCC has used the funds to recruit and support new investigators during their start-up years, to finance pilot projects by promising young researchers, to initiate new programs and develop new services that support the peerreviewed research, and to provide interim funding to researchers who show promise of obtaining renewed funding. Accordingly, the developmental funds have proven to be highly productive and have been returned many-fold in the form of follow-up peer-reviewed funding for investigators and in the fonn of scientific contributions in cancer research. In the past cycle, funds have been used to fund new investigators, support pilot projects, provide interim funding to investigators and to develop new services in our shared services such as tissue collection for our TACMA shared service, mythelation methodologies for our Genomics shared service, genetically engineered mouse models for our Experimental Mice shared service, and the development of web-based applications for our Behavioral Measurement shared service. This proposal describes the effective use of the funds and plans for future development. Annual support is request in the amount of $375,000.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023074-31
Application #
7944505
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-08-19
Project End
2014-06-30
Budget Start
2009-08-19
Budget End
2010-06-30
Support Year
31
Fiscal Year
2009
Total Cost
$513,089
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Sun, Virginia; Wendel, Christopher S; Demark-Wahnefried, Wendy et al. (2018) Diet and Behavior Modifications by Long-term Rectal Cancer Survivors to Manage Bowel Dysfunction-Associated Symptoms. Nutr Cancer :1-11
Downs, Charles A; Johnson, Nicholle M; Tsaprailis, George et al. (2018) RAGE-induced changes in the proteome of alveolar epithelial cells. J Proteomics 177:11-20
Rak, Michael A; Buehler, Jason; Zeltzer, Sebastian et al. (2018) Human Cytomegalovirus UL135 Interacts with Host Adaptor Proteins To Regulate Epidermal Growth Factor Receptor and Reactivation from Latency. J Virol 92:
Mushtaq, Adeela; Kapoor, Vikas; Latif, Azka et al. (2018) Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol 125:1-11
Bea, Jennifer W; de Heer, Hendrik Dirk; Valdez, Luis et al. (2018) Physical Activity among Navajo Cancer Survivors: A Qualitative Study. Am Indian Alsk Native Ment Health Res 25:54-73
Rojo de la Vega, Montserrat; Zhang, Donna D; Wondrak, Georg T (2018) Topical Bixin Confers NRF2-Dependent Protection Against Photodamage and Hair Graying in Mouse Skin. Front Pharmacol 9:287
Stanton, Annette L; Wiley, Joshua F; Krull, Jennifer L et al. (2018) Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes. J Consult Clin Psychol 86:820-830
Siyahian, Aida; Malik, Saad Ullah; Mushtaq, Adeela et al. (2018) Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 24:1483-1489

Showing the most recent 10 out of 1336 publications